Viotechnology company Vaxart Inc (NASDAQ:VXRT) revealed on Thursday that its investigational oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in an animal model based on a Duke University-led study and published in bioRxiv.
The company said that its oral tablet vaccine is better at reducing shedding than the injectable flu vaccine comparator, consistent with its Phase II human flu challenge study as well as induces robust systemic and mucosal responses in the preclinical study.
This study used hamster infection and aerosol transmission system to study the potential impact of oral vaccination on transmission of SARS-CoV-2. Animals received oral, intranasal or intramuscular vaccines targeting S protein and a control group received a mock vaccination. The mucosally vaccinated hamsters infected fewer hamsters and created less severe clinical symptoms than did unvaccinated hamsters. The study suggests mucosal vaccines may protect not only vaccinated, but unvaccinated animals, said the company.
Following intranasal delivery of SARS-CoV-2 and detection of substantial amounts of viral RNA in nasal swabs, the vaccinated hamsters had decreased viral RNA and infectious virus in the nose and lungs and experienced less lung pathology and lost less weight versus the mock-vaccinated hamsters post challenge.
In conjunction, the company has initiated recruiting for a global Phase II clinical trial of its oral tablet COVID-19 vaccine candidate, which targets the SARS-CoV-2 viral spike (S) protein.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial